SEC Form 4 filings for ALTSHULER DAVID, 50 Northern Ave, Boston, MA 02210, USA

Insider trading of David Altshuler, a EVP, Global Research and CSO at VRTX Vertex Pharmaceuticals Incorporated

Most recently David Altshuler sold 6,403 shares worth $965,700.46 on 12 February 2018.

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2018-02-12 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Sale 6,403 $150.82 $965,700
2018-02-12
69,999
2018-02-02 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Option exercise 1,796 $91.05 $163,526
2018-02-02
51,557
2018-01-22 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Option exercise 1,796 $91.05 $163,526
2018-01-22
51,557
2018-01-16 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Sale 56,250 $156.99 $8,830,688
2018-01-16
49,761
2017-11-15 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Sale 306 $149.12 $45,631
2017-11-15
106,011
2017-08-31 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Option exercise 1,796 $91.05 $163,526
2017-08-31
107,807
2017-07-19 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Option exercise 28,979 $84.49 $2,448,436
2017-07-19
134,990
2017-06-05 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Option exercise 7,500 $72.14 $541,050
2017-06-05
113,511
2017-05-15 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Sale 181 $114.37 $20,701
2017-05-15
106,011
2017-04-28 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Option exercise 7,500 $63.14 $473,550
2017-04-28
113,511
2017-02-13 David Altshuler
EVP, Global Research and CSO
EVP, Global Research and CSO Sale 6,403 $87.68 $561,415
2017-02-13
106,011
Vertex Pharmaceuticals Incorporated logo

Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; CRISPR Therapeutics AG; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

  • Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston 02210, United States
  • vrtx.com
  • 617-341-6100
Messenger